International Flavors & Fragrances (IFF) FY2025 results: revenue $10.9 billion, down 5.2% on the year
International Flavors & Fragrances Inc. (IFF) reported revenue of $10.9 billion for fiscal 2025, the year ended 31 December 2025, down 5.2% on the year before. Net income was -$361 million, and diluted earnings per share $-1.41. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2026.
this yearthe year beforeHover a bar for its figure.
The year in brief
What management said about the year
Guidance figures: 6 new.
- Goodwill charge sits in reported loss: Loss before taxes was $412 million and reported EPS was $(1.46). The result includes a $1,153 million goodwill impairment for the Food Ingredients reporting unit.
- Adjusted EBITDA up 7% comparable: Adjusted operating EBITDA was $2.086 billion. Comparable currency neutral growth was 7%, led by volume growth, productivity gains and favorable net pricing.
- Adjusted EPS ex amortization $4.20: Adjusted EPS excluding amortization was $4.20 per diluted share for the full year, compared with $4.22 in 2024.
- Fourth-quarter EBITDA margin 16.9%: Adjusted operating EBITDA was $437 million, a 16.9% margin. Comparable currency neutral adjusted operating EBITDA rose 7%, led primarily by productivity gains.
- Pipeline cited amid macro uncertainty: Management said macroeconomic uncertainty persists, and cited the strength of the pipeline and the benefits of reinvestment actions as reasons for confidence entering 2026.
From this 10-K
IFF creates and manufactures products used in food, beverage, health and biosciences and scent, along with adjacent products including natural health ingredients. Its customers make dairy, meat, beverages, snacks, savoury and sweet foods, baked goods, personal care products, soaps and detergents, cleaning products, perfumes, dietary supplements, food protection, infant, elderly and animal nutrition, functional food, bio-fuel and oral care products. The United States was approximately 28% of sales in 2025, no other country was more than 10%, and no customer was 10% or more. In 2025 the business ran five segments, Taste, Food Ingredients, Health and Biosciences, Scent, and Pharma Solutions until that business was sold in May 2025; the former Nourish segment was split into Taste and Food Ingredients on 1 January 2025.
The four quarters: Q1 FY2025 · Q2 FY2025 · Q3 FY2025 · Q4 FY2025
Income statement (profit and loss)
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Revenue | 10,890 | 11,484 | 11,479 | -5.2% | |
| Cost of revenue | 6,952 | 7,360 | 7,798 | -5.5% | |
| Gross profit | 3,938 | 4,124 | 3,681 | -4.5% | |
| Gross margin | 36.2% | 35.9% | 32.1% | ||
| Research and development | 694 | 671 | 636 | +3.4% | |
| Selling, general and administrative | 1,834 | 1,995 | 1,787 | -8.1% | |
| Operating income | -382 | 766 | -2,110 | ||
| Operating margin | -3.5% | 6.7% | -18.4% | ||
| Interest expense | 229 | 305 | 380 | -24.9% | |
| Pre-tax income | -412 | 308 | -2,518 | ||
| Income tax | -53.0 | 41.0 | 69.0 | ||
| Effective tax rate | n/a | 13.3% | n/a | ||
| Net income | -361 | 263 | -2,591 | ||
| Net margin | -3.3% | 2.3% | -22.6% | ||
| Diluted EPS | -$1.41 | $1.04 | -$10.14 |
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.Cash flow
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Operating cash flow | 850 | 1,070 | 1,455 | -20.6% | |
| Capital expenditure | 594 | 463 | 503 | +28.3% | |
| Free cash flow | 256 | 607 | 952 | -57.8% | |
| Free cash flow margin | 2.4% | 5.3% | 8.3% | ||
| Cash from investing | 2,269 | 326 | 558 | +596.0% | |
| Cash from financing | -3,091 | -1,606 | -1,851 | ||
| Depreciation and amortisation | 962 | 1,015 | 1,142 | -5.2% | |
| Share-based compensation | 88.0 | 77.0 | 65.0 | +14.3% | |
| Buybacks | 38.0 | 0.0 | 0.0 | ||
| Dividends paid | 409 | 514 | 826 | -20.4% | |
| Dividend per share | $1.60 | $1.60 | $3.24 | 0.0% | |
| Diluted shares, weighted | 256m | 256m | 255m | 0.0% | |
| Shares outstanding at period end | 256m | 256m | 255m | 0.0% |
Balance sheet
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Shareholders' equity | 14,154 | 13,834 | 14,611 | +2.3% | |
| Non-controlling interest | 32.0 | 35.0 | 31.0 | -8.6% | |
| Redeemable equity | n/a | n/a | 0.0 | ||
| Debt | 5,994 | 8,977 | 10,071 | -33.2% | |
| Operating lease liabilities | 533 | 550 | 642 | -3.1% | |
| Finance lease liabilities | 20.0 | 18.0 | 18.0 | +11.1% | |
| Other liabilities | 4,806 | 5,253 | 5,605 | -8.5% | |
| Total liabilities and equity | 25,539 | 28,667 | 30,978 | -10.9% | |
| Fixed assets | 4,029 | 3,739 | 4,240 | +7.8% | |
| Goodwill | 8,269 | 9,080 | 10,635 | -8.9% | |
| Intangible assets | 6,043 | 6,445 | 8,357 | -6.2% | |
| Cash and equivalents | 590 | 469 | 703 | +25.8% | |
| Receivables | 1,731 | 1,624 | 1,726 | +6.6% | |
| Inventory | 2,245 | 2,133 | 2,477 | +5.3% | |
| Other assets | 2,632 | 5,177 | 2,840 | -49.2% | |
| Total assets | 25,539 | 28,667 | 30,978 | -10.9% |
10-K for the year ended 31 December 2025, filed 27 February 2026: the filing.